1st Quarter - Report

STUDENTS FOR SENSIBLE DRUG POLICY for STUDENTS FOR SENSIBLE DRUG POLICY

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Civil Rights/Civil Liberties CIV

STATES 2.0 Act (HR 2934): Issues related state cannabis laws and provisions to enable interstate commerce. PREPARE Act (HR 2935): Issues related to the establishment of a federal commission to design a pathway for full federal cannabis regulation. Evidence-Based Drug Policy Act (HR 3082): Issues related to the authorization of federal agencies to study cannabis legalization and stops requiring the Drug Czar to oppose reform efforts. MORE Act (HR 5068): Issues related to the removal of cannabis from the Controlled Substances Act, expunging certain past convictions, and reinvesting in communities disproportionately harmed by prohibition. The End Needless Distribution of 7-OH Act (H.R. 8000): Issues related to restricting the distribution of synthetic 7-OH products by treating them as a federally controlled substance with no accepted medical use.

LobbyistCovered position, as disclosed
GINA GIORGIO —
KAT MURTI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2935 (119th), H.R. 5068 (119th), H.R. 8000 (119th), H.R. 3082 (119th), H.R. 2934 (119th)

Veterans VET

Veterans Cannabis Use for Safe Healing Act (HR 966): Issues related to the denial of VA benefits to veterans enrolled in state-approved medical cannabis programs and requiring VA providers to discuss and document cannabis use and adjust treatment. Veterans Equal Access Act (HR 1384): Issues related to the authorization of the VA to offer veterans recommendations and opinions regarding participation in their state's respective cannabis programs. Innovative Therapies Centers of Excellence Act of 2025 (HR 2623): Issues related to the designation of at least five VA medical facilities as Innovative Therapies Centers of Excellence.

LobbyistCovered position, as disclosed
KAT MURTI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2623 (119th), H.R. 1384 (119th), H.R. 966 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.